DekaBank Deutsche Girozentrale
ONCT

DekaBank Deutsche Girozentrale’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-26
Closed -$60K – 997
2013
Q4 		$60K Buy
26
+1
+4% +$2.29K ﹤0.01% 796
2013
Q3 		$70K Buy
+25
New +$124K ﹤0.01% 759

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ONCT Position: Q1 2014 in Review

DekaBank Deutsche Girozentrale sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2014, closing a stake of 26 shares — an estimated $60K sold.

DekaBank Deutsche Girozentrale first reported a position in ONCT in Q3 2013 and held it in 2 quarters. The position peaked at $70K in Q3 2013. 55 funds tracked by Wall St. Rank hold ONCT as of Q1 2014.

  • DekaBank Deutsche Girozentrale reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 26 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2014, an estimated $60K.
  • DekaBank Deutsche Girozentrale first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's Oncternal Therapeutics, Inc. Common Stock position peaked at $70K in Q3 2013.
  • 55 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2014.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2014, filed 15 May 2014.